Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 1, 2024
Data Byte

Five PDUFA dates on FDA’s October agenda

Decisions include Opdivo as perioperative therapy for NSCLC, and a Lumakras combination for mCRC
BioCentury | Mar 14, 2024
Deals

AstraZeneca’s Amolyt takeout among largest ever for a French biotech

Deal for $800M up front adds hypoparathyroidism asset, now in Phase III, to AZ’s Alexion portfolio; shareholders could receive $250M milestone
BioCentury | Feb 24, 2017
Clinical News

DB1038: Ph I started

BioCentury | Mar 28, 2016
Clinical News

Mycapssa octreotide: Phase III started

BioCentury | May 25, 2015
Company News

Antisense Therapeutics, Cortendo deal

BioCentury | Mar 9, 2015
Clinical News

Octreotide acetate: Additional Phase III data

BioCentury | Feb 16, 2015
Clinical News

Octreolin octreotide acetate: Phase III data

BioCentury | Sep 8, 2014
Clinical News

ATL1103: Additional Phase II data

Items per page:
1 - 10 of 81